Bremelanotide Dosing & Reconstitution Guide

Bremelanotide is administered via subcutaneous injection, commonly utilizing an autoinjector for convenience and precision. The dosing protocol stipulates that the compound should be used as needed, with a recommended administration occurring at least 45 minutes prior to anticipated sexual activity. Research indicates that the effective dose range for Bremelanotide is approximately 1.75 mg. This dosage aligns with findings from clinical studies, which have explored its pharmacodynamics and therapeutic potential. Precise adherence to dosing guidelines is essential, as variations may impact both efficacy and safety outcomes. It is important to note that individual responses can vary significantly, necessitating a careful consideration of dosing parameters in research settings.

The safety profile of Bremelanotide reveals several common adverse effects, with nausea being reported in 40% of cases, often of mild to moderate intensity and diminishing with continued use. Other notable effects include flushing (20%), injection site reactions (13%), and headache (11%). Additionally, a transient increase in blood pressure, with an average systolic increase of 3 mmHg and diastolic increase of 2 mmHg, has been observed within 12 hours post-administration, typically resolving within the same timeframe. Skin hyperpigmentation has been documented in 1% of patients, particularly affecting areas of darker skin, potentially linked to melanocortin-1 receptor (MC1R) cross-activation and may not completely resolve after discontinuation. Contraindications include uncontrolled hypertension or existing cardiovascular disease due to the risk of transient blood pressure elevation, as well as concurrent use with naltrexone or naltrexone-containing products, which can diminish efficacy through interactions within the melanocortin pathway. Individuals with hypersensitivity to Bremelanotide or any of its components should also refrain from its use.